Qizhi Tang, PhD, a Diabetes Center faculty member and Associate Professor of Surgery, is focused on improving islet transplantation, a minimally invasive procedure that has the potential to cure type 1 diabetes. Tremendous progress has been made in the past two decades to transform this treatment from an experimental concept to a clinical reality.
We'd like to introduce you to a new member of the Diabetes Center, Srinath Sanda, MD. Dr. Sanda received his undergraduate degree at UC San Diego, his medical degree at UC Davis, and completed his residency training in internal medicine and pediatrics at Cedars Sinai Medical Center in LA. He then went on to complete a pediatric endocrinology fellowship at UC San Diego where he worked in the immunology laboratory of Dr. Matthias von Herrath.
UCSF researchers led by Feroz Papa, MD, PhD, have discovered a molecule, TXNIP, which initiates inflammation that leads to the death of the insulin-producing beta cells in the pancreas. Published in the journal Cell Metabolism, Dr.
In May 2011, the UCSF Diabetes Center Diabetes Family Fund for Innovative Patient Care, Education and Scientific Discovery awarded its first grants to twelve groups of collaborators. As a special feature for our readers, we will continue to spotlight these groups and their progress in our future newsletters. In this issue, we are featuring The Bigger Picture (TBP) campaign between UCSF’s Center for Vulnerable Populations (UCSF CVP) http
An epidemic is sweeping the nation and world: diabetes. Almost 26 million children and adults in the United States – and 346 million worldwide – have the disease. Another 79 million Americans are considered to have pre-diabetes.
The Madison Clinic for Pediatric Diabetes is creating GreenDot, an open mobile health platform that enables both patients and health care providers to collect, aggregate, store, analyze and display diabetes-related data wirelessly and in real-time to better control blood sugars. Last month, the Madison Clinic was named one of five finalists in the Sanofi US Innovation Challenge,http://www.datadesigndiabetes.com
Denmark-based pharmaceutical company Novo Nordisk recently awarded Diabetes Center faculty member Fred Schaufele, PhD, with a Diabetes Innovation Award to study the challenge of insulin resistance at the cellular level. Dr. Schaufele seeks to understand why chronically elevated insulin found in patients with insulin resistance causes a dramatic change in insulin receptor structure, leading to even more insulin resistance and ultimately type 2 diabetes.
The Diabetes Teaching Center’s newest innovation, DiabetesIQ, was awarded Outstanding Mobile Application in the Web Marketing Associations’ 2012 MobileWebAward Competition. This free mobile app was created using the educational content found on Diabetes Education Online, www.deo.ucsf.edu, and is available on the Apple iTunes store and Google Android market.
A dedicated Diabetes Center supporter has captured the tale told by her grandmother well over a half century ago in a new children’s book entitled, Billy and Skipper. This delightful story is filled with old-fashioned values – love of family, adventure, problem solving and forgiveness – all to benefit one of the Diabetes Center’s research pioneers, Michael German, MD.
Mary Sullivan, DNP, RN, ANP-BC, CDE, has been selected for induction to the American Academy of Nursing. Dr. Sullivan, a longtime diabetes care professional at UCSF, will be joining a prestigious group of the nation’s top nurse researchers, policy makers, scholars, executives, educators, and practitioners. Previously, Dr. Sullivan was named Diabetes Educator of the Year by the American Association of Diabetes Educators (AADE).
The national research program called Type 1 Diabetes TrialNet recently screened their 100,000th family member for autoantibodies as part of the Natural History Study, now known as the Pathway to Prevention. UCSF is proud to have been selected as one of the first TrialNet Clinical Centers just over a decade ago. For relatives of people with type 1 diabetes who are not yet diagnosed -- but who are at risk for type 1 diabetes -- there are now promising clinical trials available.
A new study has been launched that seeks to evaluate differences in the immune systems of those who have had type 1 diabetes for five or more years and who still make some insulin, versus those with type 1 diabetes who do not make insulin. It will also establish a blood bank for future studies of type 1 diabetes. Led by pediatric diabetes program director Steve Gitelman, MD, and endocrine fellow Hilary Thomas, MD, the study seeks volunteers who are:
The Diabetes Center has created a new industry partnership with international pharmaceutical company, Sanofi. The goal of this alliance is to identify novel therapeutic targets for the creation of new diabetes drugs that will improve the lives of those battling both type 1 and type 2 diabetes.